STAAR SURGICAL CO STAA
Nasdaq · XNAS · stock · Ophthalmic Goods
Chart by TradingView
1/9
Piotroski F — financial health
4.46
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2026 | $239.4M | -$80.4M | $182.4M | -$40.0M | $344.2M |
| 2024 | $313.9M | -$20.2M | $239.6M | -$7.7M | $397.3M |
| 2023 | $322.4M | $21.3M | $252.7M | -$3.6M | $386.0M |
| 2022 | $239.4M | $39.7M | $223.4M | $17.6M | $336.1M |
| 2021 | $230.5M | $27.5M | $178.6M | $30.3M | $261.6M |
| 2021 | $163.5M | $5.9M | $118.4M | $12.5M | $197.2M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.46 (safe)
- Working capital / assets 0.538
- Retained earnings / assets -0.328
- EBIT / assets -0.203
- Equity / liabilities 3.202
Source: SEC EDGAR filings · CIK 0000718937 · as of 2026-01-02. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.